Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPArE: Enbrel in Psoriatic Arthritis
NCT00127842Phase 4Completed
- Sponsor
- Amgen
- Start
- Aug 2005
- Primary completion
- Aug 2005
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, open-label, single-arm trial of etanercept in psoriatic arthritis (PsA), sponsored by Amgen. Primary endpoint: Percentage of Participants With Improvement of ≥ 0.50 Units From Baseline to Month 24 in the Health Assessment Questionnaire Disability Index. Started Aug 2005; status: completed.
02
Drugs
etanercept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00127842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127842.